» Articles » PMID: 35198469

Disease Stability in Segmental and Non-Segmental Vitiligo

Overview
Specialty Dermatology
Date 2022 Feb 24
PMID 35198469
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Some therapeutic decisions in vitiligo depend on the likelihood of the disease remaining stable and inactive.

Aim: To determine a period of disease stability in vitiligo following which reactivation was unlikely.

Materials And Methods: This cross-sectional descriptive study was carried out in 200 patients where a detailed clinical history of the disease activity and stability over the course of vitiligo was recorded.

Results: There were 167 (83.5%) patients with non-segmental vitiligo and 33 (16.5%) with segmental vitiligo. For every 1-year increase in the duration of the disease, stable and active periods increased by 0.7 and 0.3 years, respectively in non-segmental vitiligo and by 0.9 and 0.1 years in segmental vitiligo ( < 0.01). When segmental vitiligo was stable for at least 2 years, it was five times less likely to re-activate than the disease that was stable for less than 2 years ( = 0.16). However, in non-segmental vitiligo, we found no association between the duration of stability and risk of reactivation.

Conclusions: Segmental vitiligo usually becomes inactive after the disease has been stable for 2 years. Non-segmental vitiligo is prone to reactivation even after prolonged periods of stability.

Citing Articles

Vitiligo and the microbiome of the gut and skin: a systematic review.

Nigro A, Osman A, Suryadevara P, Cices A Arch Dermatol Res. 2025; 317(1):201.

PMID: 39777551 DOI: 10.1007/s00403-024-03679-6.


Exploring the Potential Molecular Mechanism of Sijunzi Decoction in the Treatment of Non-Segmental Vitiligo Based on Network Pharmacology and Molecular Docking.

Du Z, Wang H, Gao Y, Zheng S, Kou X, Sun G Clin Cosmet Investig Dermatol. 2023; 16:821-836.

PMID: 37033783 PMC: 10075956. DOI: 10.2147/CCID.S403732.


Management of Stable Vitiligo-A Review of the Surgical Approach.

Grochocka M, Welniak A, Bialczyk A, Marek-Jozefowicz L, Tadrowski T, Czajkowski R J Clin Med. 2023; 12(5).

PMID: 36902772 PMC: 10004352. DOI: 10.3390/jcm12051984.

References
1.
Taneja N, Sreenivas V, Sahni K, Gupta V, Ramam M . A cross-sectional study of spontaneous repigmentation in vitiligo. Indian J Dermatol Venereol Leprol. 2019; 86(3):240-250. DOI: 10.4103/ijdvl.IJDVL_409_18. View

2.
Moellmann G, Scollay D, Nordlund J, LERNER A . Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol. 1982; 79(5):321-30. DOI: 10.1111/1523-1747.ep12500086. View

3.
Park J, Jung M, Lee J, Yang J, Lee D, Park K . Clinical course of segmental vitiligo: a retrospective study of eighty-seven patients. Ann Dermatol. 2014; 26(1):61-5. PMC: 3956796. DOI: 10.5021/ad.2014.26.1.61. View

4.
Shoukry Awad S . Depigmentation during vitiligo activity spares epithelial grafted areas. J Cosmet Dermatol. 2016; 15(4):383-386. DOI: 10.1111/jocd.12243. View

5.
Sitek J, Loeb M, Ronnevig J . Narrowband UVB therapy for vitiligo: does the repigmentation last?. J Eur Acad Dermatol Venereol. 2007; 21(7):891-6. DOI: 10.1111/j.1468-3083.2007.01980.x. View